Roots Analysis

FEBRUARY 20, 2022

In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the prime reasons that leads to failure in obtaining approval authorization. Nanoparticles Contract Manufacturing.

Contract Manufacturing 52

Contract Manufacturing Bioavailability Manufacturing Drug Delivery Systems 52

Roots Analysis

MARCH 13, 2022

Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. The Evolving Landscape of Biopharmaceutical Excipient Manufacturing Domain. Biopharmaceutical excipients can range from simple inert entities to complex compounds.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

The Pharma Data

JANUARY 27, 2021

Construction of commercial drug manufacturing facility in Germany. Development of oral biosensor and contract development & manufacturing. Psychedelic transdermal and sublingual drug formulation development.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52